Here, we will see why investors should take advantage of the recent sell-off to pick up the otherwise pricey DexCom (DXCM).
Company overview
Founded in 1999 and is headquartered in San Diego, California, DexCom is a medical device company focused on developing and commercializing CGM (continuous glucose monitoring) systems for diabetes patients. The company went public in 2005.
DexCom is revolutionizing the continuous glucose monitoring space.
DexCom had 650,000 net active patients globally on its CGM systems at the end of 2019. The company's G6 CGM (continuous glucose monitoring) system is emerging as